RITEMVIA

This brand name is authorized in Austria, Cyprus, Estonia, Lithuania, New Zealand, Poland

Active ingredients

The drug RITEMVIA contains one active pharmaceutical ingredient (API):

1 Rituximab UNII 4F4X42SYQ6 - RITUXIMAB

Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes. The antigen is expressed on >95% of all B cell non-Hodgkin’s lymphomas. Read about Rituximab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RITEMVIA Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FA01	Rituximab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FA CD20 (Clusters of Differentiation 20) inhibitors
Discover more medicines within L01FA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1749797, 1780589
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1083424, 1085386
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 19645, 19646
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100392310, 100417910